Cargando…
Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine
BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to v...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397116/ https://www.ncbi.nlm.nih.gov/pubmed/36016943 http://dx.doi.org/10.3389/fimmu.2022.938378 |
_version_ | 1784772064186466304 |
---|---|
author | Peng, Mian Dou, Xiaowen Zhang, Xiuming Yan, Mingchen Xiong, Dan Jiang, Ruiwei Ou, Tong Tang, Aifa Yu, Xiqiu Zhu, Feiqi Li, Weiqin |
author_facet | Peng, Mian Dou, Xiaowen Zhang, Xiuming Yan, Mingchen Xiong, Dan Jiang, Ruiwei Ou, Tong Tang, Aifa Yu, Xiqiu Zhu, Feiqi Li, Weiqin |
author_sort | Peng, Mian |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to vaccination with three doses of inactivated SARS-CoV-2 vaccine were followed in a cohort of 37 healthy adults (18–59 years old). Blood samples were collected at multiple time points and submitted to peptide array, machine learning modeling, and sequence alignment analyses, the results of which were used to generate vaccine-induced antibody-binding region (VIABR) immunosignatures (Registration number: ChiCTR2200058571). RESULTS: Antibody spectrum signals showed vaccination stimulated antibody production. Sequence alignment analyses revealed that a third vaccine dose generated a new highly represented VIABR near the A570D mutation, and the whole process of inoculation enhanced the VIABR near the N501Y mutation. In addition, the antigen conformational epitopes varied between short- and long-term samples. The amino acids with the highest scores in the short-term samples were distributed primarily in the receptor binding domain (RBD) and N-terminal domain regions of spike (S) protein, while in the long-term samples (12 weeks after the 2(nd) dose), some new conformational epitopes (CEs) were localized to crevices within the head of the S protein trimer. CONCLUSION: Protective antigenic epitopes were revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine inoculation. A third dose results in a new top-10 VIABR near the A570D mutation site of S protein, and the whole process of inoculation enhanced the VIABR near the N501Y mutation, thus potentially providing protection from strains that have gained invasion and immune escape abilities through these mutation. |
format | Online Article Text |
id | pubmed-9397116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93971162022-08-24 Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine Peng, Mian Dou, Xiaowen Zhang, Xiuming Yan, Mingchen Xiong, Dan Jiang, Ruiwei Ou, Tong Tang, Aifa Yu, Xiqiu Zhu, Feiqi Li, Weiqin Front Immunol Immunology BACKGROUND: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation. METHODS: The immune responses to vaccination with three doses of inactivated SARS-CoV-2 vaccine were followed in a cohort of 37 healthy adults (18–59 years old). Blood samples were collected at multiple time points and submitted to peptide array, machine learning modeling, and sequence alignment analyses, the results of which were used to generate vaccine-induced antibody-binding region (VIABR) immunosignatures (Registration number: ChiCTR2200058571). RESULTS: Antibody spectrum signals showed vaccination stimulated antibody production. Sequence alignment analyses revealed that a third vaccine dose generated a new highly represented VIABR near the A570D mutation, and the whole process of inoculation enhanced the VIABR near the N501Y mutation. In addition, the antigen conformational epitopes varied between short- and long-term samples. The amino acids with the highest scores in the short-term samples were distributed primarily in the receptor binding domain (RBD) and N-terminal domain regions of spike (S) protein, while in the long-term samples (12 weeks after the 2(nd) dose), some new conformational epitopes (CEs) were localized to crevices within the head of the S protein trimer. CONCLUSION: Protective antigenic epitopes were revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine inoculation. A third dose results in a new top-10 VIABR near the A570D mutation site of S protein, and the whole process of inoculation enhanced the VIABR near the N501Y mutation, thus potentially providing protection from strains that have gained invasion and immune escape abilities through these mutation. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9397116/ /pubmed/36016943 http://dx.doi.org/10.3389/fimmu.2022.938378 Text en Copyright © 2022 Peng, Dou, Zhang, Yan, Xiong, Jiang, Ou, Tang, Yu, Zhu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Peng, Mian Dou, Xiaowen Zhang, Xiuming Yan, Mingchen Xiong, Dan Jiang, Ruiwei Ou, Tong Tang, Aifa Yu, Xiqiu Zhu, Feiqi Li, Weiqin Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title | Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title_full | Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title_fullStr | Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title_full_unstemmed | Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title_short | Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine |
title_sort | protective antigenic epitopes revealed by immunosignatures after three doses of inactivated sars-cov-2 vaccine |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397116/ https://www.ncbi.nlm.nih.gov/pubmed/36016943 http://dx.doi.org/10.3389/fimmu.2022.938378 |
work_keys_str_mv | AT pengmian protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT douxiaowen protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT zhangxiuming protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT yanmingchen protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT xiongdan protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT jiangruiwei protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT outong protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT tangaifa protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT yuxiqiu protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT zhufeiqi protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine AT liweiqin protectiveantigenicepitopesrevealedbyimmunosignaturesafterthreedosesofinactivatedsarscov2vaccine |